Our Focus
We are a clinical-stage biotechnology company pioneering a new class of medicines designed to bring safe and efficacious treatments for cancer and severe liver diseases to patients.
Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on nearly 15 years of research into galectin modulators. By employing our world-leading expertise in galectin biology, we began by developing product candidates to modulate central disease pathways simultaneously and work synergistically with and enhance the efficacy of other therapeutics. In October 2024, we bolstered our existing oncology pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML).
Our mission is to extend the healthy lifespan of patients by providing easily administered, highly efficacious, and well-tolerated treatments that enable long-term use and significantly improve quality of life.
